• Shopping Cart
    There are no items in your cart

CLSI C49 A : 1ED 2007

Superseded

Superseded

A superseded Standard is one, which is fully replaced by another Standard, which is a new edition of the same Standard.

View Superseded by

ANALYSIS OF BODY FLUIDS IN CLINICAL CHEMISTRY

Available format(s)

Hardcopy , PDF

Language(s)

English

Published date

25-08-2018

Superseded date

29-03-2023

Superseded by

CLSI C49 ED2E : 2018

€276.45
Excluding VAT

Abstract
Committee Membership
Foreword
1 Scope
2 Standard Precautions
3 Terminology
  3.1 Glossary of Body Fluids
  3.2 Definitions
4 Matrix Effects on Clinical Laboratory Measurements
  4.1 Scientific Basis
  4.2 External Survey Data
5 Pathogenesis and Composition of Accumulation Fluids
  5.1 Amniotic
  5.2 Cerebrospinal Fluid
  5.3 Serous Fluids
  5.4 Synovial
6 Clinically Significant Analytes in Body Fluids
  6.1 Creatinine
  6.2 Amylase/Lipase
  6.3 Bilirubin
  6.4 Total Protein/Albumin
  6.5 Triglycerides
  6.6 Cholesterol
  6.7 Tumor Antigens/Markers
  6.8 Electrolytes
  6.9 pH
7 Recommendations for Alternate Sample Types Not Specified
  in Manufacturers' Claims
  7.1 Elements of Method Verification
  7.2 Assessing Body Fluid Determinations for Validity
  7.3 Precondition
  7.4 Considerations for Use of Tests for Body Fluids Other
      Than Those for Which the Methods Have Been Formally
      Validated
  7.5 Clinically Unique Samples
  7.6 Result Reporting
References
Summary of Delegate Comments and Subcommittee Responses
The Quality Management System Approach
Related CLSI/NCCLS Publications

Provides guidance for the application of widely available measurement procedures for testing body fluids and for reporting and interpreting those results.

DevelopmentNote
Supersedes NCCLS C49 P. (05/2007)
DocumentType
Miscellaneous Product
ISBN
1-56238-638-7
Pages
56
PublisherName
Clinical Laboratory Standards Institute
Status
Superseded
SupersededBy

CLSI EP10 A2 : 2ED 2002 PRELIMINARY EVALUATION OF QUANTITATIVE CLINICAL LABORATORY METHODS
CLSI M29 A3 : 3ED 2005 ACQUIRED INFECTIONS; APPROVED GUIDELINE

€276.45
Excluding VAT